Huang Lab Announces Presentations at the 2024 American Society for Hematology Annual Meeting
SAN ANTONIO, Texas — The Huang Lab at the Mays Cancer Center at UT Health San Antonio will present new findings in hematopoietic stem cell biology and therapeutic mechanisms at the 2024 Annual Meeting of the American Society for Hematology (ASH). Presenters include Gang Huang, PhD, and postdoctoral scholars Maiko Sezaki, PhD, and Jie Bai, PhD. The team will also share collaborative data on AND017 with Kind Pharmaceutical.
Jie Bai will deliver an oral presentation, “Chromatin Modifier Hmga1 Maintains Hematopoietic Stem Cell Integrity in Stress Conditions,” in Session 501, Epigenetic and Metabolic Control of Hematopoiesis, on Saturday, December 7, 2024, at 9:45 AM.
Maiko Sezaki will present the oral talk, “Luspatercept Promotes Heme Biosynthesis and Erythroblast Island Formation in a Novel Low‑Risk MDS Mouse Model,” in Session 636, Novel Mechanisms of Aberrant Hematopoiesis and Immune Evasion in MDS, on Monday, December 9, 2024, at 2:45 PM.
Gang Huang and collaborators will present two poster studies on Sunday and Monday evenings. “Pharmacological Evaluation of a First‑in‑Class Hemoglobin Elevating Agent (HbEA) AND017 in Townes SCD Mouse Model” appears in Session 113 on Sunday, December 8, 2024, from 6:00 to 8:00 PM. “Pharmacological Evaluation of a First‑in‑Class Hemoglobin Elevating Agent (HbEA) AND017 in a Mouse MDS Model of an Inducible Mutant c‑Myc Knock‑in” appears in Session 604 on Monday, December 9, 2024, from 6:00 to 8:00 PM. These AND017 studies are conducted in collaboration with Kind Pharmaceutical.
The lab will also present the poster “Loss of Cpt1a Results in Elevated Mitochondrial Reactive Oxygen Species from Glucose‑Fueled Oxidative Phosphorylation and Defective Hematopoietic Stem Cells” in Session 501, Poster III, on Monday, December 9, 2024, from 6:00 to 8:00 PM.
“These studies connect chromatin regulation, mitochondrial metabolism, and therapeutic response. They point to actionable biology across anemia, MDS, SCD, and stem cell function,” said Dr. Huang. “Our collaboration with Kind Pharmaceutical advances preclinical work aimed at improving anemia across diseases.”
About the Huang Lab
The Huang Lab at UT Health San Antonio is a basic and translational cancer research group within the MD Anderson Mays Cancer Center at UT Health San Antonio. Our team integrates hematology and solid tumor biology with immunology and metabolism to uncover mechanisms and design interventions. We advance cell and biologic therapies, including CAR T‑cell approaches for solid tumors. We also conduct research in trauma and military health. We move discoveries toward clinical impact through product development and collaborations with clinicians and industry. Education and mentorship are core to our mission. We train students, postdoctoral fellows, and early‑career scientists in rigorous, multidisciplinary research. Together, we aim to deliver therapies and technologies that improve patient outcomes.
About Kind Pharmaceutical
KIND is a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat hematological diseases and cancers. The company’s mission, “kind to human, humble to science, good to patients”, drives its commitment to advancing current science to meet unmet medical need. KIND’s lead clinical candidate, AND017, first-in-class hemoglobin elevating agent (HbEA), is being developed for treating anemia of various disorders, including dialysis dependent chronic kidney disease (DD-CKD) associated anemia, non-dialysis dependent (NDD) CKD associated anemia, cancer related anemia (CRA), myelodysplastic syndromes (MDS) anemia, sickle cell disease (SCD), and β-thalassemia. KIND’s second clinical candidate, AND019, an orally available brain penetrant selective estrogen receptor degrader (SERD), is being developed to treat ER+/Her2- breast cancer. KIND is also developing promising disruptive next generation ADC technologies.